EP0236329A1 - Amino-salicylic acid derivatives and pharmaceutical compositions - Google Patents

Amino-salicylic acid derivatives and pharmaceutical compositions

Info

Publication number
EP0236329A1
EP0236329A1 EP86900097A EP86900097A EP0236329A1 EP 0236329 A1 EP0236329 A1 EP 0236329A1 EP 86900097 A EP86900097 A EP 86900097A EP 86900097 A EP86900097 A EP 86900097A EP 0236329 A1 EP0236329 A1 EP 0236329A1
Authority
EP
European Patent Office
Prior art keywords
amino
hydroxy
benzoic acid
formula
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP86900097A
Other languages
German (de)
English (en)
French (fr)
Inventor
Giancarlo Sportoletti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ITAL-FARMACO SpA
Italfarmaco SpA
Original Assignee
ITAL-FARMACO SpA
Italfarmaco SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ITAL-FARMACO SpA, Italfarmaco SpA filed Critical ITAL-FARMACO SpA
Publication of EP0236329A1 publication Critical patent/EP0236329A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid

Definitions

  • the residue is taken up with 100 ml of acetone and 10 ml of water, 0.68 g of imidazole base are added and the mixture is stirred overnight. After solvent evaporation under reduced pressure, the residue is treated with ethyl acetate. The organic phase is washed with water, diluted hydrochloric acid- and water to neutrality. After drying on sodium sul- phate and filtration, the solvent is evaporated under vacuum. The residue is crystallized from ethanol/water. Yield: 28 g (72%) .
  • the test has been performed according to Di Rosa et al. (Di Rosa M. , Giround J.P., Willoughby D.A. - J. Path. Bact., vol. 104, 15, 1971).
  • a 1% solution (0.15 ml) of carrageenin in 0.9% NaCl was injected into the pleural cavity of Sprague-Dawley rats, weighing about 250 g.
  • the animals were sacrificed, the pleural exudate volumes were measured and the leukocytes total number was counted by a micro- cell-counter, being the cavity rinsed by 0.5 ml of a sali- ne medium.
  • the % inhibition of leukocytes total number was calcu ⁇ lated versus control animals.
  • the assayed compounds were administered orally, 1 mM/kg, 30' before the carrageenin injection in the pleural cavity.
  • Table IV as not limi ⁇ ting example, the results obtained with some of the compo ⁇ unds of the invention are reported.
  • the assay has been performed according to Gemmel et al. (Gemmel D.K. Cottney J., Lewis A.J. - Agents Actions, vol. 9, 107, 1979). 1 Ml of a rabbit anti-bovine-albumin serum (freeze-dried antibodies, dissolved in 2 ml of 0.9% NaCl) was injected into the caudal vena of Sprague-Dawley male rats.
  • the assay has been performed according to Sharon (Sharon P., Stenson W.F. - Gastroenterology, vol. 88, 55, 1985) .
  • the administered doses (via intra-bowel, during the bowel ligature and the local injection of the acetic acid) were 0.5 mM/kg, for all the tested compounds, dispersed" in carboxymethylcellulose. The % reduction of the ulceration index has been calculated versus untreated animals.
  • the compounds of Table 1 have been subjected to the acute toxicity test in mice, by the oral route, in carbo ⁇ xymethylcellulose suspensions. All the LD proved to be higher than 1600 mg/kg.
  • the doses will be dependent on the patient's weight, age and conditions and will be anyhow ranging from 50 to 1000 mg, from 1 to 4 times a day.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP86900097A 1984-11-29 1985-11-26 Amino-salicylic acid derivatives and pharmaceutical compositions Withdrawn EP0236329A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT23799/84A IT1196348B (it) 1984-11-29 1984-11-29 Composti ad attivita'antiinfiammatoria
IT2379984 1984-11-29

Publications (1)

Publication Number Publication Date
EP0236329A1 true EP0236329A1 (en) 1987-09-16

Family

ID=11210091

Family Applications (1)

Application Number Title Priority Date Filing Date
EP86900097A Withdrawn EP0236329A1 (en) 1984-11-29 1985-11-26 Amino-salicylic acid derivatives and pharmaceutical compositions

Country Status (12)

Country Link
EP (1) EP0236329A1 (OSRAM)
JP (1) JPS62501703A (OSRAM)
KR (1) KR870700608A (OSRAM)
CN (1) CN85109554A (OSRAM)
AU (1) AU5231186A (OSRAM)
DK (1) DK346486A (OSRAM)
ES (1) ES8701717A1 (OSRAM)
GR (1) GR852834B (OSRAM)
IT (1) IT1196348B (OSRAM)
PT (1) PT81566B (OSRAM)
WO (1) WO1986003199A1 (OSRAM)
ZA (1) ZA859035B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9017711D0 (en) * 1990-08-13 1990-09-26 May & Baker Ltd New compositions of matter
GB9017710D0 (en) * 1990-08-13 1990-09-26 May & Baker Ltd New compositions of matter
IT1244873B (it) * 1990-09-12 1994-09-12 Depha Team Srl Derivati dell'acido 5-aminosalicilico (5-asa) per la terapia delle infiammazioni croniche intestinali
US5366987A (en) * 1991-08-22 1994-11-22 Warner-Lambert Company Isoxazolyl-substituted alkyl amide ACAT inhibitors
FR2738150B1 (fr) * 1995-09-01 1997-10-31 Synthelabo Utilisation de la sulphasalazine et de ses metabolites pour la fabrication d'un medicament utile dans le traitement de l'insuffisance veineuse et des ulceres veineux
ATE275127T1 (de) * 2000-04-19 2004-09-15 Neurotech Co Ltd Verbindungen, zusammensetzungen und verfahren zur vorbeugung der neurodegeneration bei akuten oder chronischen verletzungen des zentralen nervensystems
US6964982B2 (en) 2000-04-20 2005-11-15 Neurotech Co., Ltd. Compounds, compositions and methods for preventing neurodegeneration in acute and chronic injuries in the central nervous system
NO20013534L (no) * 2000-07-18 2002-01-21 Koyo Chemical Company Ltd Anvendelse av en blanding omfattende et glucosaminsalt eller et glucosaminderivat for fremstilling av et medikament for behandling av human trombose
DE60136260D1 (de) 2001-01-19 2008-12-04 Apex Biotechnology Corp Nicht-enzymatischer, Detergenzien enthaltender Einweg-Elektrodestreifen für den Nachweis von Harnsäure oder Hämoglobin,sowie Verfahren für die Produktion und Anwendung desgleichen
WO2003024448A2 (en) 2001-09-14 2003-03-27 Methylgene, Inc. Inhibitors of histone deacetylase
JP4113957B2 (ja) 2002-06-19 2008-07-09 アムコア ファーマ, インコーポレイテッド テトラフルオロベンジル誘導体及びこれを含有する急性及び退行性脳神経系疾患の予防及び治療用薬学的組成物
KR100668111B1 (ko) 2005-07-28 2007-01-12 (주)에스에이치제약 강력한 항산화 효과를 가짐으로써 급성 및 퇴행성 뇌신경계질환의 예방 및 치료에 이용 가능한 신규물질인아미노살리실산 유도체와 그 염의 제조방법
ES2690205T3 (es) 2006-04-13 2018-11-19 Neurotech Pharmaceuticals Co., Ltd. Composición farmacéutica para tratar o prevenir enfermedades inflamatorias
CN100422721C (zh) * 2006-05-26 2008-10-01 南京大学 一种利用糖基萘酚的铝离子检测方法
RU2010120675A (ru) * 2007-10-23 2011-11-27 Инститьют Оф Медисинал Молекьюлар Дизайн, Инк. (Jp) Ингибитор продуцирования pai-1
KR100852962B1 (ko) 2007-11-12 2008-08-20 주식회사 뉴로테크 2-하이드록시-5-페닐알킬아미노벤조산 유도체 및 이의 염의제조방법
SI2315740T1 (en) * 2008-07-08 2018-03-30 Catabasis Pharmaceuticals, Inc. Fatty acids acetylated salicylates and their uses
US9085527B2 (en) 2008-07-08 2015-07-21 Catabasis Pharmaceuticals, Inc. Fatty acid acylated salicylates and their uses
KR101204108B1 (ko) * 2009-02-09 2012-11-22 주식회사 지엔티파마 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도
USRE46608E1 (en) 2009-09-01 2017-11-14 Catabasis Pharmaceuticals, Inc. Fatty acid niacin conjugates and their uses
RU2569063C2 (ru) 2009-09-01 2015-11-20 Катабэйсис Фармасьютикалз, Инк. Конъюгаты жирных кислот и ниацина и их применение
NZ701832A (en) * 2012-05-23 2016-08-26 Cellix Bio Private Ltd Compositions and methods for treatment of inflammatory bowel disease
US9822135B2 (en) 2012-10-30 2017-11-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. STAT3 dimerization inhibitors
KR20210107828A (ko) * 2018-12-28 2021-09-01 주식회사 지엔티파마 신경퇴행성 질환 치료를 위한 조성물 및 방법
CN111116395B (zh) * 2019-12-27 2023-04-07 湖北工业大学 多碘代芳香酸类化合物及其在抗腺病毒7型中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR4546M (OSRAM) * 1964-06-09 1966-11-02
NL7008623A (OSRAM) * 1969-06-25 1970-12-29
JPS5640710B2 (OSRAM) * 1973-01-18 1981-09-22
JPS6056130B2 (ja) * 1978-03-20 1985-12-09 久光製薬株式会社 新規なサリチル酸誘導体
US4536346A (en) * 1983-05-06 1985-08-20 American Cyanamid Company Aralkanamidophenyl compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8603199A1 *

Also Published As

Publication number Publication date
GR852834B (OSRAM) 1986-03-27
AU5231186A (en) 1986-06-18
IT1196348B (it) 1988-11-16
IT8423799A0 (it) 1984-11-29
ES8701717A1 (es) 1986-12-01
CN85109554A (zh) 1986-07-23
DK346486D0 (da) 1986-07-21
ZA859035B (en) 1986-08-27
PT81566B (en) 1987-04-07
KR870700608A (ko) 1987-12-30
WO1986003199A1 (en) 1986-06-05
PT81566A (en) 1985-12-01
ES549359A0 (es) 1986-12-01
DK346486A (da) 1986-07-21
JPS62501703A (ja) 1987-07-09

Similar Documents

Publication Publication Date Title
WO1986003199A1 (en) Amino-salicylic acid derivatives and pharmaceutical compositions
US4443475A (en) Amides of acyl-carnitines, process for preparing same and pharmaceutical compositions containing such amides
KR100343243B1 (ko) 항-염증성및/또는진통성활성을가지는니트릭에스테르들과그제조방법
JPS595196A (ja) ホスフイニルアルカノイル置換プロリン類のエステル
CA1334972C (en) Pyridine-2,4- and -2,5-dicarboxylic acid amides, processes for their preparation, the use thereof, and medicaments based on these compounds
NL8002828A (nl) 2-(mercapto-1-oxoalkyl)-1,2,3,4-tetrahydroisochinoline- -3-carbonzuren en hun derivaten.
JPS6229566A (ja) 新規グアニジノメチル安息香酸誘導体
NL8903132A (nl) Capsaicinederivaten, werkwijzen voor hun bereiding, farmaceutische preparaten die ze bevatten en hun toepassing als farmaceutica.
US4096256A (en) 7-Acyl-3-(ureidoalkyl substituted tetrazolylthiomethyl) cephalosporins, antibacterial compositions containing them, and methods of treating bacterial infections using them
JPS63216872A (ja) 複素環式化合物
KR910000646A (ko) (아릴설폰아미도-및 피리딜-또는 이미다졸릴-) 치환된 카복실산 및 이의 유도체
US4496735A (en) Certain pyridyloxy-or-thio-phenyl propenoic acid derivatives
US4404214A (en) 2-Pyridinecarboxamide derivatives compositions containing same and method of using same
US4510142A (en) Derivatives of biphenyl alkyl carboxylates and their use as medicaments
CZ322092A3 (en) N-(alpha-substituted pyridinyl)carbonyl dipeptides, process of their preparation and pharmaceutical compositions based thereon
PT90254B (pt) Processo para a preparacao de amidas de acidos ciclometileno -1,2-dicarboxilicos com actividade terapeutica e de composicoes farmaceuticas que as contem
EP0349902A2 (en) Processes for the preparation of morniflumate and analogous compounds
IE60205B1 (en) Pharmaceutically useful derivatives of thiazolidine-4-carboxylic acid
Paliwal et al. Synthesis and biological evaluation of mutual prodrugs of carboxylic group containing some non-steroidal anti-inflammatory drugs and propyphenazone
US4478843A (en) 5-Phenyltetrazoles and their use as salidiuretics
US5238948A (en) Pyridine-2,4- and -2,5-dicarboxylic acid derivatives and medicaments based on these compounds
FI68622C (fi) Foerfarande foer framstaellning av indolaettiksyraderivat
US4311699A (en) Aminoacid derivatives of cephalosporin compounds
JPH05331164A (ja) アンジオテンシンii拮抗性イソインドール誘導体
JPS6041665A (ja) 血中脂肪減少活性を有する化合物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19870520

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17Q First examination report despatched

Effective date: 19880816

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19881228

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SPORTOLETTI, GIANCARLO